327 related articles for article (PubMed ID: 26889976)
41. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy.
Kurtul N; Eroglu C; Unal D; Tasdemir EA; Orhan O; Zararsiz G; Baran M; Kaplan B; Kontas O
Asian Pac J Cancer Prev; 2014; 15(20):8911-6. PubMed ID: 25374228
[TBL] [Abstract][Full Text] [Related]
43. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
44. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis.
Wang HY; Li YY; Shao Q; Hou JH; Wang F; Cai MB; Zeng YX; Shao JY
J Transl Med; 2012 Feb; 10():27. PubMed ID: 22321704
[TBL] [Abstract][Full Text] [Related]
45. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
46. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
Jennings CJ; O'Grady A; Cummins R; Murer B; Al-Alawi M; Madden SF; Mutti L; Harvey BJ; Thomas W; Kay EW
J Thorac Oncol; 2012 Jan; 7(1):243-8. PubMed ID: 22011668
[TBL] [Abstract][Full Text] [Related]
47. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
48. AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
Sudo H; Tsuji AB; Sugyo A; Abe M; Hino O; Saga T
Int J Oncol; 2014 Feb; 44(2):530-8. PubMed ID: 24253341
[TBL] [Abstract][Full Text] [Related]
49. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
50. Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma.
Iwanami T; Uramoto H; Nakagawa M; Shimokawa H; Yamada S; Kohno K; Tanaka F
Oncology; 2014; 86(2):109-16. PubMed ID: 24457449
[TBL] [Abstract][Full Text] [Related]
51. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
52. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
[TBL] [Abstract][Full Text] [Related]
53. Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
Yoneda K; Kuwata T; Chikaishi Y; Mori M; Kanayama M; Takenaka M; Oka S; Hirai A; Imanishi N; Kuroda K; Ichiki Y; Ohnaga T; Tanaka F
Cancer Sci; 2019 Feb; 110(2):726-733. PubMed ID: 30499156
[TBL] [Abstract][Full Text] [Related]
54. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
Wang H; Dai YY; Zhang WQ; Hsu PC; Yang YL; Wang YC; Chan G; Au A; Xu ZD; Jiang SJ; Wang W; Jablons DM; You L
Int J Oncol; 2017 Jul; 51(1):91-103. PubMed ID: 28560410
[TBL] [Abstract][Full Text] [Related]
55. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
56. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
[TBL] [Abstract][Full Text] [Related]
57. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
58. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
59. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
60. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]